Hoffmann-La Roche Inc.

Boehringer Ingelheim International Gmbh

F. Hoffmann-La Roche Ag

Klaus-Peter Kuenkele

Ralf Schumacher

Olaf Mundigl

Christian Klein

Paul Parren

Erhard Kopetzki

Wolfgang Schaefer

Jan Van De Winkel

Anja Limberg

Birgit Bossenmaier

Hubert Kettenberger

Yvo Graus

Frank Rebers

Claudio Sustmann

Manfred Schwaiger

Dietmar Reusch

Silke Hansen

Andreas Wernitznig

Martine Vriesema-van Vugt

Marie-Ange Buyse

Joerg Thomas Regula

Stephanie Staelens

Petra Rueger

Matthias Rueth

Karen Cromie

Vladimir H Voynov

Bernhard Goller

Vittoria Zinzalla

Beatrijs Strubbe

Joerg-Thomas Regula

Timothy Fenn

Juan Manuel Garcia-Martinez

Jason Ho

Christian Koessl

Saurabh Sen

Guy Georges

Matthias Koerner

Kurt Lang

Hans-Willi Krell

Ulrike Reiff

Adelbert Grossmann

Paul Adam

Pankaj Gupta

Andreas Schaubmar

Martin Lanzendoerfer

Karl-Heinz Heider

Frank Herting

Martine Van Vugt

Friederike Hesse

Elinborg Ostermann

Priyanka Gupta

Ulrich Tibes

Stephen R Comeau

Philip Nicholas Gorman

Renate Konopitzky

Friedrich Metzger

Sandeep Kumar

Stefan Foser

Abdulsalam Shaaban

David S Young

Andreas Hinz

Taneisha Ann-Tanara Mack

Beat Amrein

Aude Lemarchand

Georges Guy

Srinath Kasturirangan

David Weismann

Stefan Evers

Jörg Regula

The present invention relates to novel tri-specific binding molecules. The invention also relates to nucleic acids encoding such binding molecules; to methods for preparing such binding molecules; to host cells expressing or capable of expressing such binding molecules; to compositions comprising such binding molecules; and to uses of such binding molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Tri-specific binding molecules

This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.

TRAILR2 CDH17 binding molecules for the treatment of cancer

The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.

Glycosylated antibodies

The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.

Polypeptides antagonizing Wnt signaling in tumor cells

The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.

Nucleic acid encoding dual Fc antigen binding proteins

The present invention relates to monovalent antigen binding proteins with a CH1-CL domain exchange, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Monovalent antigen binding proteins

The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.

Biparatopic polypeptides antagonizing Wnt signaling in tumor cells

Dual FC antigen binding proteins

A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.

Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)

Method for selecting CHO cell for production of glycosylated antibodies

Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing the antibodies, and uses for the antibodies are disclosed. Antibodies against IGF-IR are implicated in antitumor therapy.

Antibody selection method against IGF-IR

Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Antibodies against IGF-IR are implicated in antitumor therapy.

Antibodies against insulin-like growth factor I receptor and uses thereof

The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Aminopyrazole derivatives

Growing community of inventors

Benediktbeuern, Germany

Klaus-Peter Kuenkele